Mithra Pharmaceuticals S.A.

MITRA

BE0974283153

Pharmaceuticals

Real-time Euronext Bruxelles Other stock markets 16:35:26 26/04/2024 BST			5-day change	1st Jan Change
0.216 ^EUR	-1.82%		-.--%	-82.78%

06-11	Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt. acquired Neuralis and Estetra from Mithra Pharmaceuticals SA.	CI
05-28	Mithra Delays AGM Amid Monetization Process	MT

Mithra Pharmaceuticals S A : Signs LSA with Alvogen for Commercialization of Estelle in Hong Kong and Taiwan

January 06, 2020 at 02:19 pm

Liege - Mithra (Euronext Brussels: MITRA), a company dedicated to Women's Health, today announces that it has signed an exclusive license and supply agreement with Alvogen for the commercialization of Estelle in Hong Kong and Taiwan.

Estelle is Mithra's novel combined oral contraceptive (COC) product candidate, containing 15 mg Estetrol (E4) and 3 mg drospirenone (DRSP).

Contact:

Tel: +32 (0)4 349 28 22

Fax: +32 (0)4 349 28 21

Email: info@mithra.com

Latest news about Mithra Pharmaceuticals S.A.

Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt. acquired Neuralis and Estetra from Mithra Pharmaceuticals SA.	06-10	CI
Mithra Delays AGM Amid Monetization Process	05-28	MT
Mithra Pharmaceuticals to Postpone the Publication of Its Annual Report 2023	04-29	CI
Mithra Pharmaceuticals Obtains Court Protection Measures	04-22	MT
Mithra Pharmaceuticals SA Reports Earnings Results for the Full Year Ended December 31, 2023	03-08	CI
Mithra Pharmaceuticals to Initiate Monetization Process Involving Sale of Assets, Business	03-05	MT
Mithra Pharmaceuticals Terminates CEO; Names CFO, COO as Successors	03-05	MT
Mithra Pharmaceuticals SA Announces CEO Changes	03-05	CI
Mithra Pharmaceuticals Exits Stake in Mayne Pharma	02-16	MT
An undisclosed buyer acquired a 5.06% stake in Mayne Pharma Group Limited from Mithra Pharmaceuticals SA for AUD 21 million	02-14	CI
Mithra: share price falls, financial visibility reduced	02-06	CF
Mithra : Goldman Sachs reduces its stake to below 3%.	12-27	CF
Mithra Pharmaceuticals Completes Pediatric Study of Contraceptive Product in Adolescent Women	12-21	MT
Mithra Signs Agreement with Gedeon Richter for Commercialization of Estelle, Donesta in China	12-04	MT
Mithra Pharmaceuticals SA and Gedeon Richter Plc. Signs Binding Head of Terms to Commercialize Estelle and Donesta in China	12-04	CI
Mithra Pharmaceuticals to Conduct Additional Data Analysis for Menopause-candidate Drug	11-30	MT
Certain Ordinary Shares of Mithra Pharmaceuticals SA are subject to a Lock-Up Agreement Ending on 26-NOV-2023.	11-25	CI
Mithra Pharmaceuticals Obtains US Patent for Contraceptive Pill	11-07	MT
Mayne Pharma Gets Additional US Patent for Contraceptive	11-06	MT
Mithra and Searchlight Pharma Sign DONESTA Licensing Agreement for Canada	26/10/23	CI
Mithra Pharmaceuticals Signs License Agreement for Menopause Drug With Canada's Searchlight Pharma	26/10/23	MT
Mithra and Searchlight Pharma Inc. Signs License and Supply Agreement for the Canadian Rights to DONESTA	26/10/23	CI
Mithra Pharmaceuticals' License Partner Files for Estelle's Marketing Approval in Japan; Shares Jump	23/10/23	MT
Mithra Announces Presentation of Positive Data on Estetrol (E4) Native Estrogen at NAMS 2023	27/09/23	CI
Mithra Pharmaceuticals SA Reports Earnings Results for the Half Year Ended June 30, 2023	26/09/23	CI

Chart Mithra Pharmaceuticals S.A.

Duration

Period

More charts

Company Profile

Mithra Pharmaceuticals SA is a Belgian biopharmaceutical company dedicated to transforming women's health by offering new choices through innovation, with a particular focus on contraception and menopause. Mithra's goal is to develop products offering better efficacy, safety and convenience, meeting women's needs throughout their life span. Mithra Pharmaceuticals S.A. explores the potential of the unique native estrogen estetrol in a wide range of applications in women health and beyond. After having successfully launched the first estetrolbased product in 2021, the contraceptive pill ESTELLE®, Mithra is now focusing on its second product DONESTA®, the next-generation hormone therapy. Mithra Pharmaceuticals S.A. also offers partners a complete spectrum of solutions from early drug development, clinical batches and commercial manufacturing of complex polymeric products (vaginal ring, implants) and complex liquid injectables and biologicals (vials, pre-filled syringes or cartridges) at its technological platform Mithra CDMO.

Sector

Pharmaceuticals

Calendar

25/09/2024 - Q2 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Ratings for Mithra Pharmaceuticals S.A.

Trading Rating

Investor Rating

ESG Refinitiv

C+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

SELL

Number of Analysts

Last Close Price

0.216 EUR

Average target price

0.1 EUR

Spread / Average Target

-53.70%

Consensus

Annual profits - Rate of surprise

Company calendar

Sector Biopharmaceuticals

	1st Jan change	Capi.
MITHRA PHARMACEUTICALS S.A.	-82.78%	16.24M
CSL LIMITED	+7.46%	100B
SAMSUNG BIOLOGICS CO.,LTD.	+8.42%	42.34B
BIOGEN INC.	-13.04%	32.76B
UCB	+80.61%	29.46B
BIOMARIN PHARMACEUTICAL INC.	-10.92%	16.31B
INCYTE CORPORATION	+1.93%	14.39B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-6.77%	12.23B
ALTEOGEN INC.	+177.16%	10.47B
SWEDISH ORPHAN BIOVITRUM AB	-0.22%	8.97B

Biopharmaceuticals